Actavis will pay $66bn in cash and stock for Allergan, which at $219 per share will generate significant returns for the Botox (onabotulinumtoxinA) maker's shareholders, including a multibillion-dollar payday for Allergan's largest shareholder Pershing Square Capital Management.
Big paydays ahead as Actavis buys Allergan for $219/share
Actavis will pay $66bn in cash and stock for Allergan, which at $219 per share will generate significant returns for the Botox (onabotulinumtoxinA) maker's shareholders, including a multibillion-dollar payday for Allergan's largest shareholder Pershing Square Capital Management.
More from Archive
More from Scrip
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.